Bill C-251 (Historical)

An Act to amend the Patent Act (patented medicines)

This bill is from the 37th Parliament, 3rd session, which ended in May 2004.

Sponsor

Dan McTeague  Liberal

Introduced as a private member’s bill. (These don’t often become law.)

Status

Outside the Order of Precedence (a private member's bill that hasn't yet won the draw that determines which private member's bills can be debated), as of Feb. 2, 2004
(This bill did not become law.)

Similar bills

C-251 (37th Parliament, 2nd session) An Act to amend the Patent Act (patented medicines)
C-454 (37th Parliament, 1st session) An Act to amend the Patent Act (patented medicines)

Elsewhere

All sorts of information on this bill is available at LEGISinfo, an excellent resource from the Library of Parliament. You can also read the full text of the bill.

Bill numbers are reused for different bills each new session. Perhaps you were looking for one of these other C-251s:

C-251 (2022) Conservation of Fish Stocks and Management of Pinnipeds Act
C-251 (2020) VIA Rail Canada Act
C-251 (2016) Ban on Shark Fin Importation Act
C-251 (2013) An Act to amend the Excise Tax Act (no GST on reading materials)
C-251 (2011) An Act to amend the Excise Tax Act (no GST on reading materials)
C-251 (2010) An Act to amend the Food and Drugs Act (trans fatty acids)

Patent ActRoutine Proceedings

October 24th, 2002 / 10:25 a.m.


See context

Liberal

Dan McTeague Liberal Pickering—Ajax—Uxbridge, ON

moved for leave to introduce Bill C-251, an act to amend the Patent Act (patented medicines)

Mr. Speaker, the bill concerns patented medicines and seeks to amend the Patent Act by repealing the power of the governor in council to make regulations preventing the infringement of the patent by any person who makes, uses, constructs or sells the patent invention solely for uses reasonably related to the development of a submission.

For the information of members, the bill addresses, for example, the inequality of regulations currently attached to the Patent Act. This concerns the rather odious practice of permitting automatic injunctions to some brand name pharmaceutical companies that are claiming patent infringement when in reality they are merely seeking a delay of entry on the market of cheaper generic drugs once an existing patent has expired.

(Motions deemed adopted, bill read the first time and printed)